Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
JAMA Surgery
|
March 26, 2015
Sustainability and long-term effectiveness of the WHO surgical safety checklist combined with pulse oximetry in a resource-limited setting: two-year update from Moldova
Rebecca Y Kim, Gifty Kwakye, Alvin C Kwok, et al.
Bulletin of the World Health Organization
|
March 12, 2016
Size and distribution of the global volume of surgery in 2012
Thomas G Weiser, Alex B Haynes, George Molina, et al.
The New England Journal of Medicine
|
October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
Ian F Tannock, Ronald de Wit, William R Berry, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2020
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
Bridget F Koontz, Karen E Hoffman, Susan Halabi, et al.
Cancer Medicine
|
July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D Tucker, Jason Zhu, Daniele Marin, et al.
The New England Journal of Medicine
|
January 18, 2013
Simulation-based trial of surgical-crisis checklists
Alexander F Arriaga, Angela M Bader, Judith M Wong, et al.
Annals of Surgery
|
November 16, 2017
Mortality Trends After a Voluntary Checklist-based Surgical Safety Collaborative
Alex B Haynes, Lizabeth Edmondson, Stuart R Lipsitz, et al.
Journal of the American College of Surgeons
|
August 15, 2015
Can 360-Degree Reviews Help Surgeons? Evaluation of Multisource Feedback for Surgeons in a Multi-Institutional Quality Improvement Project
Suliat M Nurudeen, Gifty Kwakye, William R Berry, et al.
Prostate Cancer and Prostatic Diseases
|
February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer
Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
European Urology
|
May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Matthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
JAMA Surgery
|
March 26, 2015
Sustainability and long-term effectiveness of the WHO surgical safety checklist combined with pulse oximetry in a resource-limited setting: two-year update from Moldova
Rebecca Y Kim, Gifty Kwakye, Alvin C Kwok, et al.
Bulletin of the World Health Organization
|
March 12, 2016
Size and distribution of the global volume of surgery in 2012
Thomas G Weiser, Alex B Haynes, George Molina, et al.
The New England Journal of Medicine
|
October 8, 2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
Ian F Tannock, Ronald de Wit, William R Berry, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2020
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
Bridget F Koontz, Karen E Hoffman, Susan Halabi, et al.
Cancer Medicine
|
July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer
Matthew D Tucker, Jason Zhu, Daniele Marin, et al.
The New England Journal of Medicine
|
January 18, 2013
Simulation-based trial of surgical-crisis checklists
Alexander F Arriaga, Angela M Bader, Judith M Wong, et al.
Annals of Surgery
|
November 16, 2017
Mortality Trends After a Voluntary Checklist-based Surgical Safety Collaborative
Alex B Haynes, Lizabeth Edmondson, Stuart R Lipsitz, et al.
Journal of the American College of Surgeons
|
August 15, 2015
Can 360-Degree Reviews Help Surgeons? Evaluation of Multisource Feedback for Surgeons in a Multi-Institutional Quality Improvement Project
Suliat M Nurudeen, Gifty Kwakye, William R Berry, et al.
Prostate Cancer and Prostatic Diseases
|
February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer
Ryan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
European Urology
|
May 11, 2016
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Matthew R Smith, Emmanuel S Antonarakis, Charles J Ryan, et al.
Page
of 9